This activity is part 2 in a 3-part webinar curriculum.
Program Description
The treatment landscape for pediatric patients with atopic dermatitis (AD) now encompasses oral, topical, and injectable therapies in novel medication classes. With expanding indications and treatment options, specialty pharmacists must be familiar with the safety and efficacy data for these agents and their role in the treatment of pediatric patients with AD. Clinical evidence for biologic therapies in the treatment of pediatric AD continues to emerge. This webinar will focus on the most recent trial results, dosing, and age indications for approved and emerging targeted biologics indicated for treatment of pediatric AD. Key counseling pearls on the administration and monitoring of adverse effects that can be shared with caregivers will also be discussed.
Target audience: Retail and specialty pharmacists
Type of activity: Application
Release date: September 25, 2023
Expiration date: November 25, 2023
Learner level: Foundational, Intermediate
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Identify the mechanism of action, administration, dosing, indications, and adverse effects of biologic agents used to treat moderate to severe atopic dermatitis (AD) in pediatric patients
- Analyze the safety and efficacy data for biologics in the treatment of pediatric AD
- Illustrate the role of biologics to address unmet needs in the treatment paradigm of AD in children
Danielle M. Alm, PharmD, BCPS, BCPPS
Clinical Associate Professor
Acting Vice Chair
Department of Pharmacy Practice
Philadelphia College of Pharmacy
Saint Joseph’s University
Philadelphia, Pennsylvania
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-23-327-L01-P. The activity is available for CE credit through November 25, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Danielle M. Alm, PharmD, BCPS, BCPPS
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Karleen Melody, PharmD; Abigail Dill; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms